Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E 21 versus PORTIA 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E 21 versus PORTIA 21.
ENOVID-E 21 vs PORTIA-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life: 27–36 hours (mean 30.8 h). Steady-state reached after 5–7 days. Clinical context: allows once-daily dosing with stable estrogenic effect.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
73% renal (45% as unchanged norethindrone, 20% as conjugates, 8% as other metabolites), 27% fecal via bile. Enterohepatic recirculation accounts for 15% of total clearance.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Category C
Category C
Oral Contraceptive
Oral Contraceptive